RT Journal Article
T1 Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
A1 Sanmartin Fernandez, Marcelo
A1 Anguita Sanchez, Manuel
A1 Arribas, Fernando
A1 Baron-Esquivias, Gonzalo
A1 Barrios, Vivencio
A1 Cosin-Sales, Juan
A1 Esteve-Pastor, Maria Asuncion
A1 Freixa-Pamias, Roman
A1 Lekuona, Iñaki
A1 Perez-Cabeza, Alejandro I
A1 Ureña, Isabel
A1 Vazquez Rodriguez, Jose Manuel
A1 Rafols Priu, Carles
A1 Marin, Francisco
K1 Atrial fibrillation
K1 Bleeding
K1 Major adverse cardiac events (MACE)
K1 Rivaroxaban
K1 Atroke
AB The aim of the study was to evaluate the performance of the 2MACE in patients with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE. This was a post-authorization and observational study of AF adults treated with rivaroxaban for ≥ 6 months. The primary endpoint was any of the major adverse cardiac events (MACE), namely, cardiovascular death, non-fatal myocardial infarction, and myocardial revascularization. The area under the curve (AUC) was calculated to evaluate the performance of 2MACE, and a new score, 2MACER to predict MACE. A total of 1433 patients were included (74.2 ± 9.7 years, CHA₂DS₂-VASc 3.5 ± 1.5, 26.9% 2MACE ≥ 3). The annual event rates (follow-up 2.5 years) were 1.07% for MACE, 0.66% for thromboembolic events and 1.04% for major bleeding. Patients with 2MACE ≥ 3 (vs.  In clinical practice, AF patients anticoagulated with rivaroxaban exhibit a low risk of events. 2MACE score acts as a modest predictor of a higher risk of adverse outcomes in this population. 2MACER did not significantly increase the ability of 2MACE to predict MACE.
YR 2022
FD 2022-05-04
LK http://hdl.handle.net/10668/21661
UL http://hdl.handle.net/10668/21661
LA en
DS RISalud
RD Apr 4, 2025